Find information on thousands of medical conditions and prescription drugs.

Faslodex

Fulvestrant is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects and down-regulates the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]



AstraZeneca received FDA approval for Faslodex - Branded News - Brief Article - Product Announcement
AstraZeneca received FDA approval for Faslodex (fulvestrant), a treatment for hormone receptor positive metastatic breast cancer in postmenopausal women ...
Analysis Demonstrates Time to Response With FASLODEX® Injection Comparable to Anastrozole for Postmenopausal Women With Metastatic Breast Cancer
Results from Phase III trials announced at 28th Annual San Antonio Breast Cancer Symposium SAN ANTONIO, Texas, Dec. 10 /PRNewswire-FirstCall/ -- An analysis of two Phase III studies evaluating t
Hormone trial seeks volunteers - FYI
Researchers are recruiting for a randomized, double-blinded phase III trial to assess the efficacy and tolerability of fulvestrant (Faslodex) injection.
New drugs 2003, part II
IN THIS ARTICLE, you'll learn about eight more new drugs marketed in the first half of 2002. (For details on other new drugs first marketed in that period, ...
Once-monthly treatment for refractory breast cancer
The FDA has approved Faslodex (fulvestrant) injection for the treatment of hormone receptor-- positive metastatic breast cancer in postmenopausal women ...
New treatment for advanced breast cancer - Updates
In April 2002, the FDA approved Faslodex (fulvestrant) for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women ...
Fulvestrant Promising for Advanced Breast Ca
SAN ANTONIO -- Fulvestrant, the first in a new class of drugs known as estrogen receptor downregulators, shows great promise for the treatment of breast ...
AstraZeneca Provides Additional Support to Hurricane Victims
Company launches relief efforts in partnership with Rotary Club of Houston to pledge additional support at AHA annual meeting WILMINGTON, Del., Nov.

Home Contact Resources Exchange Links ebay